Product Images Tadalafil

This is a description of Tadalafil Tablets, USP with NDC code 69238-1346-3 for once-daily use. Each film-coated tablet contains 2.5mg of Tadalafil, USP. Dosage should not be split and an entire dose should be taken. It is Rx only and should be stored at 20° to 25°C (68° to 77°F) in a tight container. The tablets are manufactured by Amneal Pharmaceuticals Pvt. Ltd. in Ahmedabad, INDIA and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ. It is important to keep this and all medications out of reach of children. There seems to be additional text that is unreadable due to error.*

This is a description of Tadalafil tablets with a concentration of 5mg per tablet. The recommended dose is provided in the accompanying literature, and the tablets should not be split. The drug should be stored between 20° to 25°C (68° to 77°F). The tablets are manufactured by Amneal Pharmaceuticals Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC.*

This is a description of Tadalafil tablets manufactured and distributed by Amneal Pharmaceuticals. It includes details on the quantity, dosage, and storage requirements of the tablets. The tablets should not be split, and the entire dose should be taken as prescribed. The tablets contain 10 mg of Tadalafil, and the usual dosage is provided in accompanying literature. The tablets should be kept in a tight container and stored at 20° to 25°C. The text also mentions the manufacturer's location and license number.*

This is a prescription medication with the National Drug Code 69238-1349-3. The medication is Tadalafil and it comes in the form of film-coated tablets of 20mg. The tablets should not be split, and the entire dose should be taken. The usual dosage should be according to the accompanying literature. It should be stored at 20° to 25°C (68° to 77°F), and this medication should be kept in a tight container and out of the reach of children. It is manufactured by Amneal Pharmaceuticals Pvt. Ltd. and Distributed by Amneal Pharmaceuticals LLC. It's an oral solid dosage unit, and the manufacturing license number is G/26/2137 Rev. 01-2019-00. However, there is a Non-Varnish Area for Lot and Exp. Dates measuring 26 x 28 mm, and it is not advisable to use this area for any treatment purpose.*

This appears to be a table or graph displaying the difference in blood pressure between a medication called Tadalafil and a placebo. The table shows standing and supine systolic and diastolic blood pressure readings. However, the table is not very legible and some characters are not recognizable, making it difficult to interpret the data.*

This appears to be a table showing the values for Standing Systolic BP and Supine Systolic BP in mmHg along with some data about Tadalafil and doxazosin medication. However, there is some gibberish text "aohowo" and "Aohowd" which are not readable.*

This is a study comparing the effects of different treatments (tadalafil, doxazosin, placebo) on systolic blood pressure. Information on dosages and administration times is provided. However, the output contains several errors and incomplete words, making it difficult to fully understand the study design.*

This is a chart showing the plasma concentration of Tadalafil in mcg/L at different time points after a single dose of 20 mg or 5 mg of Tadalafil, as well as once-daily 5 mg Tadalafil after 5 consecutive days of administration. The concentration reaches its peak at around 2 hours after administration and starts to decline gradually. Data is shown up to 120 hours (5 days) after the first dose.*

The text describes the change in IPSS Total score for Tadalafil 5mg and placebo treatment over a specified duration. The result shows statistical significance (p<0.01). No further information or context is available.*

The text shows a comparison study between Tadalafil 5 mg and a placebo medication. The effectiveness of Tadalafil is denoted by a significant difference in the IPSS Total Score compared to the placebo medication. The duration of the treatment is also mentioned, but further details or conclusions cannot be made with this limited information.*

The text describes a comparison between Tadalafil 5mg and Placebo in relation to the change from the baseline in IPSS total score. It also states that the statistical analysis resulted in a significant difference between the two groups (p<0.01). However, no information is provided about the study design, objectives or outcomes other than the duration of treatment in weeks.*